The prevalence of heart failure (HF) in the U.S. is increasing hand-in-hand with rising rates of diabetes and obesity, according to a recent analysis, and HF-related CVD death rates have followed suit—most notably in younger adults.

Heart disease is now the leading cause of maternal deaths in the U.S., the American College of Obstetricians and Gynecologists (ACOG) reported in early May, prompting the organization to publish a comprehensive guide on pregnancy and CVD.

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high proportion of people with cancer therapy-induced cardiomyopathy (CCM), researchers reported in Circulation.

Researchers at Tel Aviv University in Israel have 3D-printed what they said is the first vascularized heart using a patient’s own cells and biological materials.